Oryn Therapeutics
Cambridge, United States· Est. 2021
Developing a new class of therapeutic drug candidates based on naturally occurring theta defensins to treat diseases of immune system dysregulation.
Private Company
Total funding raised: $30M
About
Developing a new class of therapeutic drug candidates based on naturally occurring theta defensins to treat diseases of immune system dysregulation.
RNA & Gene Therapy
Funding History
2Total raised:$30M
Series A$25MMar 15, 2023
Seed$5MJun 15, 2021